Clinical Trial Update: A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD) [Phase 3]

View source ↗

Summary

A phase 3 trial update assessing long-term safety of higher doses of nusinersen (BIIB058) in SMA participants from a prior ONWARD trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• Nusinersen (nusinersen)

Snippet

Sponsor: Biogen | Conditions: Muscular Atrophy, Spinal | Phase 3 | Status: COMPLETED